CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today provided an update on the global development plan for vadadustat, an oral HIF stabilizer in global Phase 3 development for the treatment of anemia due to chronic kidney disease.
“We continue to execute on our global Phase 3 program for vadadustat. Patient enrollment in INNO2VATE and PRO2TECT is advancing, with full enrollment of these studies targeted by the end of 2018,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We anticipate top-line results for INNO2VATE and PRO2TECT in 2019, subject to the accrual of MACE events, with market launch anticipated in 2020.”
“In collaboration with our partner, Otsuka,” added Butler, “we have enhanced the study designs for FO2RWARD and TRILO2GY. We believe these changes will provide additional characterization and differentiation of vadadustat and further strengthen our commercial position upon the drug’s approval. The investment in these study enhancements reflects our confidence in the program and our desire to position vadadustat for success upon launch.”
Vadadustat Development Program Updates:
INNO2VATE and PRO2TECT Phase 3 Programs
- Full enrollment targeted by the end of 2018
- Top-line results expected in 2019, subject to the accrual of MACE events
FO2RWARD Phase 2 Study
- New study design includes a broader dialysis population in addition to hyporesponders, and a larger sample size; this study will replace the former FO2RWARD study
- Includes once-daily and three-times-weekly dosing
- Designed to generate data to inform ESA-switching protocols
- Expected to initiate in Q2 2018, with top-line results expected in late 2018 or early 2019
TRILO2GY Phase 3 Study
- New study design includes once-daily and three-times-weekly dosing and an ESA control, as well as a larger sample size; this study will replace the former TRILO2GY study
- Designed to generate data to inform switching from Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa) and Mircera®(methoxy PEG-epoetin beta)
- Expected to initiate in late 2018 or early 2019, with top-line results expected in early 2020
Japan Phase 3 Program
- Akebia’s partner, Mitsubishi Tanabe Pharma Corporation, initiated its Phase 3 program to support registration in patient populations with anemia due to non-dialysis-dependent and dialysis-dependent chronic kidney disease
- These studies do not include a MACE endpoint
- Data read-out expected in 2019
Non-Clinical Carcinogenicity Studies
- Akebia completed two carcinogenicity studies, a two-year study in rats and a six-month study in mice, results of which showed no carcinogenic effect of vadadustat
About Vadadustat
Vadadustat is an oral hypoxia-inducible factor (HIF) stabilizer currently in Phase 3 development for the treatment of anemia related to chronic kidney disease. Vadadustat exploits the same mechanism of action used by the body to adapt naturally to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin production to increase red blood cell production and, ultimately, improve oxygen delivery. Vadadustat is an investigational therapy not approved by the U.S. Food and Drug Administration or any regulatory authority.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

